2021 年第 9 期 第 16 卷

盐酸安罗替尼二线治疗老年小细胞肺癌的有效性和安全性观察

Effectiveness and safety of anlotinib hydrochloride second-line treatment on small cell lung cancer in elderly patients

作者：王宁军马银杰高业博薛鹏高音周磊朱世杰

英文作者：Wang Ningjun Ma Yinjie Gao Yebo Xue Peng Gao Yin Zhou Lei Zhu Shijie

单位：中国中医科学院望京医院肿瘤科，北京100102

英文单位：Department of Oncology Wangjing Hospital of China Academy of Chinese Medical Science Beijing 100102 China

关键词：小细胞肺癌；广泛期；盐酸安罗替尼；老年患者

英文关键词：Smallcelllungcancer;Extensivestage;Anlotinibhydrochloride;Elderlypatients

• 摘要：

• 目的 观察盐酸安罗替尼在老年小细胞肺癌患者中二线治疗的有效性和安全性。方法 选择2018年6月至2020年6月在中国中医科学院望京医院肿瘤科住院治疗的28例确诊为广泛期小细胞肺癌的老年患者为研究对象。在一线治疗进展后予以盐酸安罗替尼口服进行二线治疗。通过观察治疗后的客观有效率（ORR）、疾病控制率（DCR）及不良反应，评估盐酸安罗替尼在老年小细胞肺癌患者中二线治疗的有效性及安全性。结果 28例患者服用盐酸安罗替尼进行二线治疗后的ORR为28.6%（8/28），DCR为60.7%（17/28）。不良反应包括高血压、白细胞减少、凝血功能异常、肝肾功能异常、胃肠道反应、乏力、口腔黏膜炎、腹泻、蛋白尿等，以0～Ⅱ级为主，按需予以对症处理后缓解，严重不良反应发生率低。结论 盐酸安罗替尼在老年小细胞肺癌患者的二线治疗中效果较好，不良反应可控，可以考虑作为不能耐受化疗的老年小细胞肺癌患者的二线治疗选择。

• Objective To observe the effectiveness and safety of anlotinib hydrochloride for second-line treatment on small cell lung cancer in elderly patients. Methods From June 2018 to June 2020, 28 elderly patients with extensive stage small cell lung cancer in Department of Oncology, Wangjing Hospital of China Academy of Chinese Medical Science were selected. They were treated with anlotinib hydrochloride orally for second-line therapy after first-line treatment progress. The effectiveness and safety of anlotinib hydrochloride orally for second-line therapy on elderly patients with small cell lung cancer were evaluated by observing the objective response rate(ORR), disease control rate(DCR) and adverse reactions. Results The ORR and DCR of the 28 patients were 28.6%（8/28） and 60.7%（17/28） respectively by oral anlotinib hydrochloride for second-line treatment. Adverse effects included hypertension, leucocytopenia, coagulation dysfunction, abnormal liver and kidney function, gastrointestinal reaction, fatigue, oral mucositis, diarrhea, proteinuria and so on. The adverse effects were mostly grade 0-Ⅱ, the patients were relieved after symptomatic treatment, and the incidence of serious adverse reactions was low. Conclusions Anlotinib hydrochloride has a good effect for second-line treatment on elderly patients with small cell lung cancer, and the adverse reactions are controllable. It can be considered as a second-line treatment option for elderly patients with small cell lung cancer who cannot tolerate chemotherapy.